Nuveen LLC Buys New Position in Lyell Immunopharma, Inc. $LYEL

Key Points

• Nuveen LLC acquired a new stake in Lyell Immunopharma, Inc. during the first quarter, purchasing 641,173 shares valued at approximately $345,000.
• Several institutional investors, including Barclays PLC and Wells Fargo & Company, have increased their holdings in Lyell Immunopharma, which now has over 66% of its stock owned by such entities.
• Analysts have mixed ratings on Lyell Immunopharma, with a consensus rating of "Reduce" and an average price target of $15.00.

Nuveen LLC bought a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 641,173 shares of the company's stock, valued at approximately $345,000. Nuveen LLC owned approximately 0.22% of Lyell Immunopharma at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LYEL. Barclays PLC grew its holdings in shares of Lyell Immunopharma by 7.4% in the fourth quarter. Barclays PLC now owns 258,380 shares of the company's stock worth $165,000 after purchasing an additional 17,765 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after purchasing an additional 20,542 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Lyell Immunopharma by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company's stock worth $197,000 after purchasing an additional 36,555 shares during the last quarter. Graham Capital Management L.P. bought a new position in shares of Lyell Immunopharma in the fourth quarter worth approximately $33,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Lyell Immunopharma in the fourth quarter worth approximately $64,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. HC Wainwright restated a "neutral" rating and issued a $10.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 24th. Wall Street Zen upgraded shares of Lyell Immunopharma from a "sell" rating to a "hold" rating in a report on Monday, September 1st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Reduce" and an average price target of $15.00.

Lyell Immunopharma Stock Up 3.7%

Shares of LYEL stock opened at $12.15 on Friday. The stock has a fifty day moving average of $10.67 and a 200 day moving average of $10.35. Lyell Immunopharma, Inc. has a 52 week low of $7.65 and a 52 week high of $32.00. The firm has a market capitalization of $233.40 million, a price-to-earnings ratio of -0.50 and a beta of -0.19.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.80) by $0.91. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%. Equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

Want to see what other hedge funds are holding LYEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.